1。摘要•双盲随机对照试验(RCT)的ARCH结果表明,与单独的苯丙酸酯相比,romosozumab 210 mg皮下每月12个月,然后降低了抗逆转岩的风险(新的椎骨骨折和临床裂缝)。•参加拱门试验的患者中有90%以上是对骨质疏松药物的幼稚治疗。ARCH并非旨在为Romosozumab在不宽容或对其他骨质疏松药物(如双膦酸盐)的不宽容或不响应的人中提供信息。•以制造商的价格,对于已经由已指定的患者人群的公共药品计划偿还的治疗,Romosozumab不被认为是具有成本效益的。Cadth建议将Romosozumab至少降低53%,被认为是具有成本效益的。
• anifronlummaab (type interferon inhibitor I) – SLE/TRU (B.150), • bimekizumab (IL-17A/17F inhibitor) – SZS (B.35), ZZS (B.36) and nr-axSpA (B.82), • cankinumab (IL-1 inhibitor (IL-1 inhibitor (IL-1 beta) – the arrangement character MIZS and ch仍然在成年人(b.33),•corgitinib(Jak1抑制剂) - RWS(B.33),•Guselkumb(IL-23抑制剂) - SZS(B.35),•Nindanib(Nindanib)(酪氨酸激酶抑制剂) - slave pneumonal病) - 奴隶肺炎prefeft with slave Pneumon preffect pneumon preef in slave pneumon hiss-swave pneumon hon。 (ILD-PF)在摇摆的桶组织疾病中,包括RRR(B.135),•Rimbiczumab(IL-23抑制剂) - SZS(B.35),•romosumumb(Shebsumumb(Shebsumab(sklerostin抑制剂)) - Osteoporse pomenoporse pomenoporse(comenoporse contemenopaimab(miniizab),•B.160),•B.160),•b.160) (B.33),•Tocilizumab(Roactemr,Tyenne) - 静脉内姿势(非标签) - GCA(B.75),•Tofacienb(Jak1/Jak1/Jak3抑制剂Jak1/Jak3) - Mizs(B.33),SKSS(B.33),SKSS(B.33),ZZS(B.36)